Deleted Tweets From Scott Gottlieb, R-D.C.

The FDA and industry have to accelerate the adoption of advanced and smart manufacturing technologies to strengthen the nation’s public health infrastructure. To this end, the FDA is creating a new collaboration with @NIST. #FDAVoices https://t.co/mfpGYpWDSt

So far at the IMFs in FY 2020 the FDA has screened and refused admission to more than 34,000 products with more than 24,000 being violative drug products that were destroyed.

As we continue to fight #COVID19, FDA remains steadfast in making real time decisions based on evolving information and science. This has been consistently applied throughout the pandemic in our approach to diagnostics, PPE and potential therapies.

RT @AnandShahFDA: Having fun in the sun? Practice social distancing, wear a mask, and wash your hands. Also check out @US_FDA's lates… https://t.co/oVc60hONiM

If you’ve had #COVID19, please help your family, friends, neighbors, and fellow Americans by donating plasma today QT @WhiteHouse: "We've seen that this is a safe treatment, and we're encouraged by the early, promising data that we've seen ... Th… https://t.co/qZf6btF8oT)

RT @Mike_Pence: Wheels up to Florida with @SteveFDA to visit @umiamimedicine to mark the beginning of Phase-3 clinical trials with… https://t.co/V9sreCjsiu

Submit your questions for our next session of #AskFDA. QT @US_FDA: Let’s do it again! Join @SteveFDA as he answers your questions about anything FDA. Send your questions using… https://t.co/zsaltoO3bK)

RT @DrAbernethyFDA: It was a pleasure to participate in The Next Era of Healthcare @BloombergLive discussion including the new use of t… https://t.co/Dld8mKzpgf

We are proud to participate in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder project organized by @reaganudall in collaboration with @CancerResearch.

RT @US_FDA: Throughout its history, FDA has warned Americans against buying fraudulent medical devices. Be a #cautiousconsumer… https://t.co/m1MQhHRhy0

FDA will continue to enhance & expand its work to accelerate novel #COVID19-related therapies & intends to provide additional information in the near future to give Americans a greater understanding of the full extent of our work in this area.

Convalescent plasma & hyperimmune globulin are blood products made from the blood of recovered #COVID19 patients. Because these products contain antibodies to the disease, they may help sick #coronavirus patients by shortening the length or lessening the severity of the illness.

As part of CTAP’s work, FDA is collaborating with government, industry & academic partners to facilitate the development & use of plasma & blood products for the potential treatment of #COVID19. https://t.co/JAjUEBSy6c

FDA has, among other things redeployed medical & regulatory staff to serve on review teams dedicated to #COVID19 therapies, streamlined processes & operations for developers & scientists to send inquiries & requests, & provided resources to health care providers & researchers.

Through CTAP, FDA is triaging requests from developers & scientists seeking to develop new drug & biologic therapies, providing ultra-rapid, interactive input on protocols for both clinical trials and single-patient expanded access requests in 3 hours.

Under the leadership of @POTUS @realDonald Trump, @VP, and @SecAzar, @US_FDA recently launched the #Coronavirus Treatment Acceleration Program (#CTAP) https://t.co/eCBVHrUaDV

The donations of these medications are expected to help ease supply pressures for them. We are working with manufacturers to increase production to ensure their availability to patients who need them for treatment of malaria, lupus and rheumatoid arthritis.

An EUA may be issued if FDA determines that, amongvother criteria, the known/potential benefits of the product, when used to diagnose, prevent or treat the identified disease/condition, outweigh the known/potential risks & there are no adequate, approved, available alternatives.

No firms are reporting drug shortages due to #COVID19, including the approximately 20 drug products that are solely sourced from China. https://t.co/aNk4642Ty7

We are reaching out to manufacturers and compiling information about the supply chain at this time, but that report does not accurately reflect our current assessment.

There have been reports referencing a list of 150 drugs susceptible to shortage as a result of #coronavirus. This is incorrect information. QT @axios: SCOOP: About 150 prescription drugs are at risk of shortage if the coronavirus outbreak in China worsens, according… https://t.co/XxPyTZN0Jj)

The FDA will continue to closely monitor the domestic and global supply chain during this evolving situation. Should the agency be alerted to a potential shortage of a critical medical product, we will be as transparent as possible in sharing updates as they develop.

FDA’s new database launch is an important step in the agency’s continued commitment to the global HIV epidemic and is part of our ongoing mission to empower the public through increased access to information and data. https://t.co/oQermMpOG9

Had my first meeting with FDA senior staff yesterday. Incredible to hear about the cutting-edge work in progress and how the agency has evolved over the years since the doctor widely recognized as the first FDA Commissioner – Harvey Wiley – started his crusade for pure food. https://t.co/hjHx9smMfj

RT @FDACommissioner: I am honored to serve as the 24th Commissioner of Food and Drugs. I would like to thank @SecAzar for swearing me in… https://t.co/qSrLuu0vT3

To facilitate generic entry, competition, #lowerPrices, #FDA releases guidance on path to generic entry for 51 drugs https://t.co/jYOaj4B6Li

RT @califf001: Wonderful to see such attention to both the suffering in PR and the needs of others to benefit from the device indu… QT @SGottliebFDA: My statement on status of medical device manufacturing in Puerto Rico and continued recovery efforts on Island: https://t.co/c4P52xVuka 🇵🇷)

At #FDA we've been working closely with #HHS and @WhiteHouse to develop and coordinate a detailed response to the #opioid crisis from day #1

RT @TomBurtonWSJ: The FDA is monitoring medical device production facilities in Puerto Rico in efforts to avoid shortages of medical… QT @SGottliebFDA: My statement on status of medical device manufacturing in Puerto Rico and continued recovery efforts on Island: https://t.co/c4P52xVuka 🇵🇷)

RT @SGottliebFDA: At #FDA we've been working closely with #HHS and @WhiteHouse to develop and coordinate a detailed response to the #opioid crisis from day #1

@WhiteHouse We're developing policy responses to national crisis in close coordination. As administration leaders c… https://t.co/8nEMCA1Yeh

RT @SGottliebFDA: FDA watching for med-tech shortages in wake of Puerto Rico power grid failure: https://t.co/4g2hZ2ofNx

RT @DonnaYoungDC: Going to be quite a meeting; @SGottliebFDA to speak. Panels include @akesselheim @foxerinr Bernstein's Ronny Gal, o… QT @DrugChannels: FYI: On 11/8/17, I will be on #PBM panel for @FTC "Understanding Competition in #Prescription #Drug Markets" https://t.co/ZehxHXVpAY)

RT @FDAMedia: Statement by @SGottliebFDA on medical device manufacturing recovery in Puerto Rico: https://t.co/Byf3K63ikk

My statement on status of medical device manufacturing in Puerto Rico and continued recovery efforts on Island: https://t.co/c4P52xVuka

RT @SGottliebFDA: .@USA_FDA’s “The Real Cost” tobacco education campaign now includes messages about the risks of teen e-cig use… https://t.co/cEsBeH3ZhF

This has to be a #TwitterFirst from the very tech savvy and pioneering @EricTopol - congrats to you Eric! https://t.co/g0XeKk2MOg QT @EricTopol: A very early glimpse of our next grandchild :-) https://t.co/0ga3NJf3Lv)

RT @SGottliebFDA: Poignant essay about cancer, hardship, perseverance, and #ModernMedicine. Kudos to brilliant work of @LucetteLagnado https://t.co/QAmYQfOwS0

RT @SGottliebFDA: Read about #FDAs new comprehensive plan to reduce the death and disease from combustible cigarettes https://t.co/wDJ3B8hrKa

RT @SGottliebFDA: Register now for #FDAs Oct 30 Public Workshop: Advocacy in Rare Diseases Drug Development. Help advance treatments… https://t.co/hA8o5Wupij

Fish are protein-rich and can help with your child's growth and development. The best choices are lower in mercury:… https://t.co/o95ZxdxOub

Do a rotation with @FDAOncology - Applications invited for 8-week Oncology Center of Excellence Fellows Program… https://t.co/xgCVjSSV19

RT @FDAOncology: Watch @FDAOncology Pazdur on importance of communication among all parties in expanded access https://t.co/XMkpJDRbfM @reaganudall

RT @SGottliebFDA: Do a rotation with @FDAOncology - Applications invited for 8-week Oncology Center of Excellence Fellows Program… https://t.co/xgCVjSSV19

#FDA launches new, comprehensive campaign promoting use of #biosimilars through education, information for providers https://t.co/mjYhTwx0vS

RT @DonnaYoungDC: .@SGottliebFDA & Leah Christl on #FDA's new steps to educate docs about #biosimilars https://t.co/AHp1lvsFyq #pharma #biotech #biosimilar

RT @SarahKarlin: Interesting look at #FDA materials developed 2 educate docs on #biosimilars https://t.co/2lvhazGPKL

#FDA holds public workshop on advancing the principles of patient-focused drug development 12/18 in person or online https://t.co/pjIqEbJ0iM

RT @CraigCaplan: FDA's @SGottliebFDA & other HHS officials testify at @HouseCommerce hearing on hurricane public health preparedness… https://t.co/JMaR3qvBB2

RT @SGottliebFDA: New #FDA steps promoting medical device innovation: breakthrough pathway guidance, 1st device development tool, more https://t.co/dSkFiH9AMn

The FDA and industry have to accelerate the adoption of advanced and smart manufacturing technologies to strengthen the nation’s public health infrastructure. To this end, the FDA is creating a new collaboration with @NIST. #FDAVoices https://t.co/mfpGYpWDSt

So far at the IMFs in FY 2020 the FDA has screened and refused admission to more than 34,000 products with more than 24,000 being violative drug products that were destroyed.

As we continue to fight #COVID19, FDA remains steadfast in making real time decisions based on evolving information and science. This has been consistently applied throughout the pandemic in our approach to diagnostics, PPE and potential therapies.

RT @AnandShahFDA: Having fun in the sun? Practice social distancing, wear a mask, and wash your hands. Also check out @US_FDA's lates… https://t.co/oVc60hONiM

If you’ve had #COVID19, please help your family, friends, neighbors, and fellow Americans by donating plasma today QT @WhiteHouse: "We've seen that this is a safe treatment, and we're encouraged by the early, promising data that we've seen ... Th… https://t.co/qZf6btF8oT)

RT @Mike_Pence: Wheels up to Florida with @SteveFDA to visit @umiamimedicine to mark the beginning of Phase-3 clinical trials with… https://t.co/V9sreCjsiu

Submit your questions for our next session of #AskFDA. QT @US_FDA: Let’s do it again! Join @SteveFDA as he answers your questions about anything FDA. Send your questions using… https://t.co/zsaltoO3bK)

RT @DrAbernethyFDA: It was a pleasure to participate in The Next Era of Healthcare @BloombergLive discussion including the new use of t… https://t.co/Dld8mKzpgf

We are proud to participate in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder project organized by @reaganudall in collaboration with @CancerResearch.

RT @US_FDA: Throughout its history, FDA has warned Americans against buying fraudulent medical devices. Be a #cautiousconsumer… https://t.co/m1MQhHRhy0

FDA will continue to enhance & expand its work to accelerate novel #COVID19-related therapies & intends to provide additional information in the near future to give Americans a greater understanding of the full extent of our work in this area.

Convalescent plasma & hyperimmune globulin are blood products made from the blood of recovered #COVID19 patients. Because these products contain antibodies to the disease, they may help sick #coronavirus patients by shortening the length or lessening the severity of the illness.

As part of CTAP’s work, FDA is collaborating with government, industry & academic partners to facilitate the development & use of plasma & blood products for the potential treatment of #COVID19. https://t.co/JAjUEBSy6c

FDA has, among other things redeployed medical & regulatory staff to serve on review teams dedicated to #COVID19 therapies, streamlined processes & operations for developers & scientists to send inquiries & requests, & provided resources to health care providers & researchers.

Through CTAP, FDA is triaging requests from developers & scientists seeking to develop new drug & biologic therapies, providing ultra-rapid, interactive input on protocols for both clinical trials and single-patient expanded access requests in 3 hours.

Under the leadership of @POTUS @realDonald Trump, @VP, and @SecAzar, @US_FDA recently launched the #Coronavirus Treatment Acceleration Program (#CTAP) https://t.co/eCBVHrUaDV

The donations of these medications are expected to help ease supply pressures for them. We are working with manufacturers to increase production to ensure their availability to patients who need them for treatment of malaria, lupus and rheumatoid arthritis.

An EUA may be issued if FDA determines that, amongvother criteria, the known/potential benefits of the product, when used to diagnose, prevent or treat the identified disease/condition, outweigh the known/potential risks & there are no adequate, approved, available alternatives.

No firms are reporting drug shortages due to #COVID19, including the approximately 20 drug products that are solely sourced from China. https://t.co/aNk4642Ty7

We are reaching out to manufacturers and compiling information about the supply chain at this time, but that report does not accurately reflect our current assessment.

There have been reports referencing a list of 150 drugs susceptible to shortage as a result of #coronavirus. This is incorrect information. QT @axios: SCOOP: About 150 prescription drugs are at risk of shortage if the coronavirus outbreak in China worsens, according… https://t.co/XxPyTZN0Jj)

The FDA will continue to closely monitor the domestic and global supply chain during this evolving situation. Should the agency be alerted to a potential shortage of a critical medical product, we will be as transparent as possible in sharing updates as they develop.

FDA’s new database launch is an important step in the agency’s continued commitment to the global HIV epidemic and is part of our ongoing mission to empower the public through increased access to information and data. https://t.co/oQermMpOG9

Had my first meeting with FDA senior staff yesterday. Incredible to hear about the cutting-edge work in progress and how the agency has evolved over the years since the doctor widely recognized as the first FDA Commissioner – Harvey Wiley – started his crusade for pure food. https://t.co/hjHx9smMfj

RT @FDACommissioner: I am honored to serve as the 24th Commissioner of Food and Drugs. I would like to thank @SecAzar for swearing me in… https://t.co/qSrLuu0vT3

To facilitate generic entry, competition, #lowerPrices, #FDA releases guidance on path to generic entry for 51 drugs https://t.co/jYOaj4B6Li

RT @califf001: Wonderful to see such attention to both the suffering in PR and the needs of others to benefit from the device indu… QT @SGottliebFDA: My statement on status of medical device manufacturing in Puerto Rico and continued recovery efforts on Island: https://t.co/c4P52xVuka 🇵🇷)

At #FDA we've been working closely with #HHS and @WhiteHouse to develop and coordinate a detailed response to the #opioid crisis from day #1

RT @TomBurtonWSJ: The FDA is monitoring medical device production facilities in Puerto Rico in efforts to avoid shortages of medical… QT @SGottliebFDA: My statement on status of medical device manufacturing in Puerto Rico and continued recovery efforts on Island: https://t.co/c4P52xVuka 🇵🇷)

RT @SGottliebFDA: At #FDA we've been working closely with #HHS and @WhiteHouse to develop and coordinate a detailed response to the #opioid crisis from day #1

@WhiteHouse We're developing policy responses to national crisis in close coordination. As administration leaders c… https://t.co/8nEMCA1Yeh

RT @SGottliebFDA: FDA watching for med-tech shortages in wake of Puerto Rico power grid failure: https://t.co/4g2hZ2ofNx

RT @DonnaYoungDC: Going to be quite a meeting; @SGottliebFDA to speak. Panels include @akesselheim @foxerinr Bernstein's Ronny Gal, o… QT @DrugChannels: FYI: On 11/8/17, I will be on #PBM panel for @FTC "Understanding Competition in #Prescription #Drug Markets" https://t.co/ZehxHXVpAY)

RT @FDAMedia: Statement by @SGottliebFDA on medical device manufacturing recovery in Puerto Rico: https://t.co/Byf3K63ikk

My statement on status of medical device manufacturing in Puerto Rico and continued recovery efforts on Island: https://t.co/c4P52xVuka

RT @SGottliebFDA: .@USA_FDA’s “The Real Cost” tobacco education campaign now includes messages about the risks of teen e-cig use… https://t.co/cEsBeH3ZhF

This has to be a #TwitterFirst from the very tech savvy and pioneering @EricTopol - congrats to you Eric! https://t.co/g0XeKk2MOg QT @EricTopol: A very early glimpse of our next grandchild :-) https://t.co/0ga3NJf3Lv)

RT @SGottliebFDA: Poignant essay about cancer, hardship, perseverance, and #ModernMedicine. Kudos to brilliant work of @LucetteLagnado https://t.co/QAmYQfOwS0

RT @SGottliebFDA: Read about #FDAs new comprehensive plan to reduce the death and disease from combustible cigarettes https://t.co/wDJ3B8hrKa

RT @SGottliebFDA: Register now for #FDAs Oct 30 Public Workshop: Advocacy in Rare Diseases Drug Development. Help advance treatments… https://t.co/hA8o5Wupij

Fish are protein-rich and can help with your child's growth and development. The best choices are lower in mercury:… https://t.co/o95ZxdxOub

Do a rotation with @FDAOncology - Applications invited for 8-week Oncology Center of Excellence Fellows Program… https://t.co/xgCVjSSV19

RT @FDAOncology: Watch @FDAOncology Pazdur on importance of communication among all parties in expanded access https://t.co/XMkpJDRbfM @reaganudall

RT @SGottliebFDA: Do a rotation with @FDAOncology - Applications invited for 8-week Oncology Center of Excellence Fellows Program… https://t.co/xgCVjSSV19

#FDA launches new, comprehensive campaign promoting use of #biosimilars through education, information for providers https://t.co/mjYhTwx0vS

RT @DonnaYoungDC: .@SGottliebFDA & Leah Christl on #FDA's new steps to educate docs about #biosimilars https://t.co/AHp1lvsFyq #pharma #biotech #biosimilar

RT @SarahKarlin: Interesting look at #FDA materials developed 2 educate docs on #biosimilars https://t.co/2lvhazGPKL

#FDA holds public workshop on advancing the principles of patient-focused drug development 12/18 in person or online https://t.co/pjIqEbJ0iM

RT @CraigCaplan: FDA's @SGottliebFDA & other HHS officials testify at @HouseCommerce hearing on hurricane public health preparedness… https://t.co/JMaR3qvBB2

RT @SGottliebFDA: New #FDA steps promoting medical device innovation: breakthrough pathway guidance, 1st device development tool, more https://t.co/dSkFiH9AMn